A nurse is assessing a client who is receiving gemfibrozil. The nurse should identify which of the following findings as an adverse effect of this medication?
Dependent edema.
Muscle tenderness.
Tremors.
Hyperkalemia.
The Correct Answer is B
Choice A rationale
Dependent edema is not a common adverse effect of gemfibrozil. It is more commonly associated with other conditions such as heart failure.
Choice B rationale
Muscle tenderness is a known adverse effect of gemfibrozil. It can indicate myopathy or rhabdomyolysis, which are serious conditions that require medical attention.
Choice C rationale
Tremors are not a common adverse effect of gemfibrozil. They are more commonly associated with neurological conditions or other medications.
Choice D rationale
Hyperkalemia is not a common adverse effect of gemfibrozil. It is more commonly associated with medications that affect renal function or potassium balance. .
Free Nursing Test Bank
- Free Pharmacology Quiz 1
- Free Medical-Surgical Quiz 2
- Free Fundamentals Quiz 3
- Free Maternal-Newborn Quiz 4
- Free Anatomy and Physiology Quiz 5
- Free Obstetrics and Pediatrics Quiz 6
- Free Fluid and Electrolytes Quiz 7
- Free Community Health Quiz 8
- Free Promoting Health across the Lifespan Quiz 9
- Free Multidimensional Care Quiz 10
View Related questions
Correct Answer is D
Explanation
Choice A rationale
Immediate-release exenatide pens should be discarded 30 days after the first use, not two months. This ensures the medication remains effective and free from contamination.
Choice B rationale
Exenatide is administered subcutaneously, not intramuscularly. The preferred injection sites are the abdomen, thigh, or upper arm.
Choice C rationale
Open exenatide pens should be stored at room temperature, but this is not the most critical aspect of patient education. Proper storage ensures the medication’s stability and effectiveness.
Choice D rationale
Immediate-release exenatide should be taken one hour before morning and evening meals to optimize its glucose-lowering effects by enhancing insulin secretion in response to meals.
Correct Answer is D
Explanation
Choice A rationale
Sitagliptin is a DPP-4 inhibitor used to manage blood sugar levels in type 2 diabetes but does not specifically slow the progression of nephropathy.
Choice B rationale
Glipizide is a sulfonylurea that helps control blood sugar levels but does not have a direct effect on slowing nephropathy progression.
Choice C rationale
Metoprolol is a beta-blocker used to manage hypertension but does not specifically target nephropathy progression.
Choice D rationale
Losartan is an angiotensin II receptor blocker (ARB) that helps manage hypertension and has been shown to slow the progression of nephropathy in patients with type 2 diabetes.